Intelligence · Clinical pipeline
Oncology R&D Pipeline
Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Quick answer
Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Top sponsors
- First People's Hospital 474 programs
- Chinese Academy of 400 programs
- United Therapeutics Europe 219 programs
- George Institute for 172 programs
- Takeda 163 programs
- HOFFMANN-LA ROCHE 144 programs
- AstraZeneca 143 programs
- MSD Merck Sharp 131 programs
- Regeneron UK 128 programs
- Anaxis Pharma 125 programs
- Telethon Foundation 113 programs
- Novartis India 110 programs
Pipeline programs
-
IOR-IISML42037
The George Institute
Lung Cancer
1 trial -
IOR-REG-2501
The George Institute
Cutaneous Basal Cell Carcinoma
1 trial -
IOV-3001
Iovance Biotherapeutics B.V.
Unresectable Melanoma
1 trial -
IOV-4001
Iovance Biotherapeutics B.V.
Unresectable Melanoma
1 trial -
IOV-COM-202
Iovance Biotherapeutics B.V.
Neoplasm
1 trial -
IOV-LUN-202
Iovance Biotherapeutics B.V.
Metastatic Non-Small-Cell Lung Cancer
1 trial -
IOV-MEL-202
Iovance Biotherapeutics B.V.
Previously treated advanced melanoma
1 trial -
IPC 2022-067
The George Institute
acute myeloid leukemia
1 trial -
IPC 2024-001
The George Institute
acute myeloid leukemia
1 trial -
IPH5201-201
Lacuna Pharma Pty Ltd
Non-Small Cell Lung Cancer II, III
1 trial -
IPH6501
Lacuna Pharma Pty Ltd
Relapsed and/or Refractory CD20-expressing Non-Hodgkin Lymphoma
1 trial -
IPILIMUMAB, NIVOLUMAB
Ningbo Cancer Hospital
type B3 thymoma and thymic carcinoma
1 trial -
IPN01203
Ipsen
Advanced Solid Tumor, Metastatic Solid Tumor
1 trial -
IRINOTECAN, lurbinectedin
Lacuna Pharma Pty Ltd
Selected Advanced Solid Tumors
1 trial -
IRSSP-001
The George Institute
Patients diagnosed with unresectable and / or metastatic locoregionally advanced squamous cell carcinoma of the oral cavity, oropharynx or hypopharynx or larynx secondary to Fanconi anemia.
1 trial -
IRST100.42
Istituto Gentili S.r.l.
neuroendocrine tumors, soft tissue sarcoma
1 trial -
IRST100.59
Istituto Gentili S.r.l.
Solid tumors
1 trial -
IRST100.60
Istituto Gentili S.r.l.
NET, Neuroendocrine Tumor, Other SSTR-positive tumours, NETs retreated with PRRT, Pheochromocytomas and paragangliomas, Bronchopulmonary and other NETs
1 trial -
IRST153.09
Istituto Gentili S.r.l.
Metastatic colorectal cancer
1 trial -
IRST162.14
Istituto Gentili S.r.l.
Extensive-Stage Small-Cell Lung Cancer (ES SCLC)
1 trial -
IRST185.04
Istituto Gentili S.r.l.
metastatic castration resistant prostate cancer (mCRPC), symptomatic bone-only metastatic castration resistant prostate cancer (mCRPC)
1 trial -
IRST204.09
Istituto Gentili S.r.l.
Acute myeloid leukemia
1 trial -
ISA101b
Regeneron UK Limited
Squamous Cell Carcinoma of the Oropharynx
2 trials -
ISIS 2503
IONIS PHARMACEUTICALS INC
Pancreatic Cancer
1 trial -
ISIS EIF4E Rx
IONIS PHARMACEUTICALS INC
Non-small Cell Lung Cancer
1 trial -
ISIS EIF4E Rx
IONIS PHARMACEUTICALS INC
Castrate-Resistant Prostate Cancer
1 trial -
ITCC-054/AAML1921
Disc Medicine
Chronic Myeloid Leukemia
1 trial -
IXAZOMIB
Takeda
Follicular Lymphoma
1 trial -
Ibrutinib
Karyopharm Therapeutics Inc
Lymphoma
1 trial -
Ibrutinib 560 mg
United Therapeutics Europe Ltd
Mantle Cell Lymphoma
1 trial -
Iclusig 15 mg film-coated tablets
Ningbo Cancer Hospital
Chronic myelogenous leukemia
1 trial -
Icotinib
The First People's Hospital of Lianyungang
Non-Small Cell Lung Cancer
1 trial -
Icotinib
The First People's Hospital of Lianyungang
Esophageal Cancer
1 trial -
Idasanutlin
Hoffmann-La Roche
Follicular Lymphoma
1 trial -
Ifetroban Sodium
CUMBERLAND PHARMACEUTICALS INC
Malignant Solid Tumor
1 trial -
Ifinatamab Deruxtecan
Merck Sharp and Dohme
Esophageal squamous cell carcinoma
1 trial -
Ifinatamab deruxtecan
Daiichi Sankyo
Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC)
1 trial -
Ifinatamab deruxtecan
Daiichi Sankyo
Recurrent or Metastatic Solid Tumors (endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colorectal cancer (CRC); hepatocellular carcinoma (HCC); adenocarcinoma of esophagus, gastroesophageal junction, and stomach (Ad-Eso/GEJ/gastric); urothelial carcinoma (UC); ovarian cancer (OVC); cervical cancer (CC); biliary tract cancer (BTC); human epidermal growth factor 2 (HER2)-low breast cancer (BC); HER2 immunohistochemistry (IHC) 0 BC; and cutaneous melanoma)
1 trial -
Imgatuzumab
Centessa Pharmaceuticals plc
Cutaneous Squamous Cell Carcinoma
1 trial -
Immunological Agent
The First People's Hospital of Lianyungang
Lung Cancer Metastatic
1 trial -
Immunomodulatory DC vaccines to target prostate cancer
Shenzhen Second People's Hospital
Prostate Cancer Indications
1 trial -
Immunotherapy combined with chemotherapy
The First People's Hospital of Lianyungang
Rectal Adenocarcinoma
1 trial -
Imx-110
Immix Biopharma
Solid Tumor, Adult
1 trial -
Indibulin
Alaunos Therapeutics
Metastatic Breast Cancer
1 trial -
Induction Therapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Splenic B-cell Lymphoma/Leukaemia With Prominent Nucleoli，SBLPN
1 trial -
Induction of neo-antigen specific T cells by... for Ovarian cancer
Disc Medicine
Ovarian cancer
1 trial -
Induction therapy of GP(Pomalidomide+Obinutuzumab）
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Indolent Lymphoma
1 trial -
Inetetamab
The First People's Hospital of Lianyungang
Breast Cancer
1 trial
Frequently asked questions
How many oncology pipeline programs are tracked?
5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.
Where does pipeline data come from?
ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.